Case Report

Sijia Zhang*, Yu Xiao*, Leichong Chen*, Zhenyu Li, Yan Zong, Kuikui Zhu, Rui Meng*

Endostar plus pembrolizumab combined with a platinum-based dual chemotherapy regime for advanced pulmonary large-cell neuroendocrine carcinoma as a first-line treatment: A case report

https://doi.org/10.1515/biol-2022-0062
received October 17, 2021; accepted February 26, 2022

Abstract: Pulmonary large-cell neuroendocrine carcinoma (LCNEC) is a rare and highly aggressive cancer with a very poor prognosis. The proper treatment decision and possible prognosis outcome for advanced LCNEC is always an enormous challenge due to its scarcity. Here, we presented a 59-year-old male patient with advanced LCNEC with a non-neuroendocrine immunophenotype who received endostar plus pembrolizumab combined with a platinum-based dual chemotherapy regime as a first-line treatment. At present, the patient’s condition is well controlled by medication only and has a progression-free survival of more than 2 years. Adverse effects recorded for this patient during treatment courses include nausea, vomiting, II–III quality bone marrow toxicity, and PD-1 blockade-related hypothyroidism. This case report discussed the feasibility of immunotherapy, anti-angiogenesis agents, and chemotherapy as a first-line therapy in advanced LCNEC.

Keywords: pulmonary large-cell neuroendocrine carcinoma, immunotherapy, anti-angiogenesis, chemotherapy, combination therapy

1 Introduction

Pulmonary large-cell neuroendocrine carcinoma (LCENC) is a high-grade neuroendocrine (NE) carcinoma, accounting for 1.7–3.0% of all diagnosed lung cancer [1]. Liver (47%), bone (32%), and brain (23%) metastases were found at initial diagnosis in more than half of LCNEC patients, with a median overall survival (mOS) of 4.0 months [95% confidence interval (CI) 3.5–4.6] [1]. Up to date, the optimal treatment strategy for LCNEC is rarely known. Due to the similarity to small-cell lung carcinoma (SCLC) in clinical characteristics, common LCENC is treated with SCLC-like platinum-based doublet chemotherapeutic regimens, such as cisplatin–etoposide or cisplatin–irinotecan [2]. However, poor control rates and low progression-free survival (PFS)/overall survival (OS) are still important limitations.

Immunotherapy, PD-1/PD-L1 blockade, and anti-angiogenesis agents have antitumor activity. Synergic therapy of the above drugs with cytotoxic agents has been confirmed to prolong the survival time of patients with...
NSCLC and/or SCLC as first-line therapy. Currently, the efficiency of synergic therapy is still unclear in metastasis LCNEC. Here, we reported a case of advanced LCNEC that responded well to irinotecan–nedaplatin chemotherapy combined with immunotherapy and anti-angiogenic as the first-line therapy.

2 Case presentation

In May 2018, a 59-year-old male patient was diagnosed at a local hospital with left lung space and left pleural effusion due to sudden left chest pain. He was admitted to our hospital (Union Hospital of Tongji Medical College, Wuhan, China) the next month. The patient complained of hypertension and long history of smoking with a smoking index of over 400. Admission physical examination revealed no positive signs and the Eastern Cooperative Oncology Group (ECOG) performance status of the patient was 1. A positron emission tomography–computed tomography (CT) scan showed multiple nodules in the lingual segment of the left upper lobe, with a maximum of 2.1 cm × 2.2 cm, which was closely related to the pleura. Part of them had abnormally increased metabolism. Bilateral pleural and interlobular fissures were unevenly thickened, and multiple nodules were concentrated on the left side with increased metabolic dispersion. Multiple lymph node enlargement occurred in the mediastinum (areas 3R, 4R/L, 5, 7) and hilar of both lungs with abnormal metabolism (Figure 1). Malignant tumor lesions are mostly considered according to those mentioned above. The primary left lung with bilateral pleura, interlobular fissure, mediastinum, and bilateral hilar lymph node metastasis was likely to be left pleural effusion; there were no signs of tumor metastasis in the rest of the exploration site. On June 13, 2018, a CT-guided biopsy of the left lung was performed. Histopathology showed a non-small-cell carcinoma with NE morphology (shown in Figure 2a), which was suspected to be LCENC, but the NE marker was negative. Immunohistochemical (IHC) results are summarized in Table 1, and all the positive staining is presented in Figure 2b–f. PD-L1 expression status was not tested due to the deficiency of the puncture biopsy. Brain magnetic resonance imaging (MRI) excluded brain metastases. Next-generation sequencing (NGS) analysis using 556 cancer-related gene panels revealed a total of 6 non-synonymous somatic mutations (4 missenses, 2 introns). Based on the above results, this patient was diagnosed with c-stage IVA, cT2N3M1b (pleura) (AJCC8th TNM classification).

A standard platinum-based doublet chemotherapy regime (nedaplatin 60 mg and irinotecan 100 mg) was utilized for two treatment cycles. Post-treatment CT showed stable disease (SD). To make the persistent control of the patient’s condition, standard chemotherapy was used in combination with both 100 mg pembrolizumab once per cycle and continual 48KU/micropump endostar 1 week per cycle. The platinum-based regime was abandoned after four cycles. One hundred milligrams of pembrolizumab once per cycle and continual 48KU/micropump endostar 1 week per cycle continued nine cycles. During the whole treatment, CT still showed SD, which is shown in Figure 3a and b. Occasionally nausea and discomfort that occurred in a patient during the chemotherapy could be relieved by himself. Hypothyroidism associated with PD-1 blockade was diagnosed in a patient after 11 cycles of using pembrolizumab and was rapidly relieved by oral administration of thyroxine tablets. Serum levels of FT3, FT4, and TSH during this period are shown in Figure 4 and Table A1.

The maintenance of the treatment plan was discontinued from January 2020 to May 2020 due to the unexpected COVID-19. On May 27, 2020, the patient returned...
to our hospital and was found with a large amount of pericardial effusion. Fortunately, pericardial puncture and drainage and pericardial perfusion therapy maintained good control of effusion. Subsequent pathological examination of pericardial drainage fluid sediment showed very few dyskaryotic cells. Immunohistochemistry was then performed and the results were as follows: paranuclear punctate (PCK) (+), CK8/18 (+), TTF-1 (+), PGP9.5 (+), Ki67 (+), CD117 (−), SOX10 (−), Syn (−), CgA (−), CD56 (−), CK7 (−), NapsinA (−), and P40 (−) in the tumor cells and Claudin-4 (+), PCK (+), CK8/18 (−), Calretinin (−), CK5/6 (−), CD68 (−), TTF-1 (−), and PGP9.5 (−) (shown in Table 1). In addition, no new lesions were found in neck, chest, and abdomen enhanced CT, brain enhanced MRI, and systemic bone emission computed tomography ECT as shown in Figure 3b. However, the serum CA125 level was elevated to 46.4 ng/mL. Therefore, experts of in-hospital MDT (multi-disciplinary team) were required to reevaluate his situation, but there was no adequate evidence to support disease progression. These experts advised that the patient should continuously receive 100 mg pembrolizumab once per cycle. Thereafter, the disease remained stable under observation for approximately 6 months, during which the CA125 level slowly increased from 46.4 to 79.9 ng/mL. Up to December 2020, CA125 rapidly increased to 287.8 ng/mL as shown in Figure 5. The patient’s disease progressed after 30 months of anti-tumor treatment.

Table 1: Results of IHC staining

| Immunohistochemistry                                      | Status          |
|----------------------------------------------------------|-----------------|
| Puncture biopsy of the left lung (tumor cells)            |                 |
| PCK (paranuclear punctate+), CK8/18, TTF-1, PGP9.5, Ki67 (≤90%) | Positive        |
| CD117, SOX10, Syn, CgA, CD56, CK7, NapsinA, P40           | Negative        |
| Pericardial effusion sediment (dyskaryotic cells)         |                 |
| Claudin-4, PCK                                           | Positive        |
| CK8/18, Calretinin, CK5/6, CD68, TTF-1, PGP9.5            | Negative        |

Informed consent: Informed consent has been obtained from all individuals included in this study.

Ethical approval: The research related to human use has been complied with all the relevant national regulations and institutional policies and in accordance with the tenets of the Declaration of Helsinki and has been approved by the authors’ institutional review board or equivalent committee.
Figure 3: Treatment process and therapeutic effect. (a) Schematic diagram of the patient's clinical treatment process. (b) Chest CT (computed tomography) scanning. PD, progressive disease.
3 Discussion

Pulmonary LCENC is a high-grade non-small-cell NE carcinoma classified as a variant of large-cell carcinoma in the updated WHO classification of lung tumors [3]. There are four major types of NE phenotypes in large-cell carcinoma. One of them is large-cell carcinoma with NE morphology but non-NE immunophenotype [4], which is generally similar to LCENC [5,6]. The optimal chemotherapy regimen of stage IV pLCENC as a first-line treatment remains controversial. Because LCNEC and SCLC have similar neuroendocrine morphology and biomarker expression, it is difficult to distinguish the difference between them. Generally speaking, there is no clear standard treatment for LCNEC in clinics and some scholars recommend EP as the first choice for treatment. Our case report showed an experience of treatment of advanced pLCENC without NE phenotype as the first-line therapy.

In the first-line treatment, two prospective single-arm phase II studies for advanced LCNEC that performed a platin-based doublet regimen of SCLC like had a positive effect during the short term. One study enrolled a total of 44 patients with the treatment of cisplatin–irinotecan, and the response rate was 54.5%, with the median PFS (mPFS) and mOS of 5.9 and 15.1 months, respectively [7]. Another trial showed an objective response rate of 38% and a disease control rate of 64% among 42 patients with cisplatin and etoposide treatment. The mPFS and mOS were 5.3 and 7.7 months, respectively [8].

With the development of NGS technology, studies of the genetic environment in LCNEC have explained a series of variants that differed from normal tissue and brought great benefits in identifying therapeutic drugs. George et al. provided a very comprehensive multi-omics analysis of LCNEC and revealed TP53 (92%), RB1 (42%), LKB1/STK11 (30%), as well as KEAP1 (22%) mutations [9]. Furthermore, they found that loss of heterozygosity, biallelic alterations, and larger genomic rearrangements were the main reasons for somatic alterations of RB1 and STK11/KEAP1, and these were mutually exclusive. Thus, two separate subtypes can be divided molecularly based on mutation evidence. Type I is defined by STK11/KEAPI
alterations and has an NE phenotype with the high expression of ASCL1 and DLL3 but the downregulation of the NOTCH pathway. In contrast, type II is characterized by RBI alterations but predominantly non-NE phenotype, high expression of REST and NOTCH, and activation of immune cell response. Lantuejoul et al. indicated that RFI therapy ± IC inhibitors and type II from SCLC treatment [10]. RFI expression by IHC staining is another significant evaluation indicator. Derks et al. showed that pLCNEC patients with RFI wild-type and/or expressing RFI have superior overall survival when treated with NSCLC-like chemotherapy compared to SCLC-like (9.6 vs 5.6 months), but with no difference in the outcome for patients with inactivated RFI [11]. Our patient accepted NGS analysis and revealed a total of six non-synonymous somatic mutations (four missenses, two introns). Unfortunately, none of the related gene mutations reported above were found. According to these results, we preliminarily speculated that the better response of immunotherapy might be related to the type of the detected mutations because some patients with LCNEC are not effective against immune checkpoint inhibitor drugs. Like literature reported by Han et al., this patient (staged at IIIA with pLCNEC) was treated with thoracoscopic radical surgery for upper left lung cancer and postoperative chemotherapy with a double-drug regimen holding platinum. Then, bevacizumab, paclitaxel, and the PDL1 checkpoint inhibitor nivolumab were applied, but the patient's disease progressed rapidly. Even with positive PD-L1 expression, immunotherapy is an ineffective treatment for these patients. Researchers thought that a possible contributing factor is the timing of immunotherapy too late [12]. In addition, the tumor was effectively controlled when the patient in our study achieved nedaplatin-irinotecan agents. We speculated that the molecular phenotype of the patient might be SCLC like because of non-NE markers and high Ki-67 index (90%), but the platinum-based dual regimen did not make his tumor essentially regress. The risk of recurrence in the short term because of potential SCLC-like characteristics. Among other variant targets, KRAS mutations in LCNEC are the most common (approximately 22–24%) and can be associated with adverse responses to chemotherapy [13,14]. Nonetheless, EGFR and BRAF mutations in LCNEC are very low, nearly 2 and 1%, respectively, which is different from NSCLC [14]. Therefore, EGFR-TKIs may not be satisfactory for the efficacy of LCNEC.

In immunotherapy, PD-1/PD-L1 inhibitors, which activate natural antitumor immune responses by disrupting the linkage of PD-1 to PD-1 ligand, have been observed to be effective in treating NSCLC, SCLC, and/or LCNEC. Studies by Sherman et al. [15] and Levra et al. [16] showed that single-agent immune checkpoint inhibitors (ICI) as a second line or multiple line for the treatment of patients with advanced LCNEC were associated with 33 and 60% of total ORR, respectively. Eleven percentage (2/21) of patients had a complete response (CR) in Sherman's study. mPFS was 4.2 months and 57 weeks. In addition, synergistic regimens of ICI plus chemotherapy have not only been testified to shrink tumor diameter and achieve a major pathological response (MPR) in the period of neoadjuvant therapy [17] but also have been found to control disease progression [18] in advanced LCNEC. To date, information on the use of PD-1/PD-L1 inhibitors in first-line advanced LCNEC is very sparse. Recently, PD-L1 blockades, atezolizumab, and durvalumab in combination with platinum-based chemotherapy have sequentially been approved for the first-line treatment of extensive-stage SCLC (ES-SCLC) patients deriving from Impower130 trail and CASPIN trail, respectively. It implied that metastatic LCNEC, like ES-SCLC, could be used in synergetic therapy with immunchemotherapy as the first-line therapy. Both PD-L1 expression and tumor mutation burden (TMB) are important biomarkers for response to immunotherapy in NSCLC or SCLC. In advanced LCNEC, several prior studies reported that PD-L1 expression rates were 10–20% [19,20]. The median TMB has been represented to be 9.9 muts/Mb in pLCNEC [21], compared to NSCLC (median 5.7 muts/Mb) [19], which indicated that LCNEC patients have a potential advantage in making a PD-1/PD-L1 inhibitor efficient. Zhang et al. described an LCENC patient with high TMB (25.8 muts/Mb) but negative PD-L1 who achieved a CR after nivolumab treatment when the tumor rapidly progressed after surgery and adjuvant therapy [22]. Xu et al. reported a case of a patient who was staged at cTibN3M0 IIIIB with locally advanced pulmonary LCNEC. After surgical resection and chemoradiotherapy, the patient achieved complete remission. PD-L1 (+) results were >50% in this case, so PD-L1 inhibitor durvalumab was then started to consolidate the treatment. After six courses of immune maintenance therapy, the patient developed grade 2 immune-related pneumonitis and took prednisone orally until the symptoms resolved, and then reached complete remission again [12,23]. In our case, TMB is 2.77 muts/Mb, and PD-L1 expression is undetected due to the inadequacy of biopsy. To strive for more than survival time, pembrolizumab was synergized with nedaplatin-irinotecan treatment for our patient. However, low TMB for our patient prompted the integration of other treatment manners.
Angiogenesis inhibitors directly fight against vascular endothelial growth factor (VEGF), which influences tumor growth inhibition. In the GOIRC-AIFA trial, bevacinumab was added to the first-line dual chemotherapy for ED-SCLC treatment, which showed a small, statistically significant improvement in PFS (5.7 vs 6.7 months; hazard ratio, 0.72; 95% CI, 0.54–0.97), but with no difference in OS [24]. In pLCENC, angiogenesis inhibitors are rarely experienced. A few studies reported overexpression of VEGF in pLCENC. Iyoda et al. explored potential molecular targets in pLCENC, and they found that 13/13 (100%) tumors exhibited high VEGF expression as compared to 13/14 (92.9%) tumors of lung adenocarcinomas (ACs), suggesting a possible role for anti-VEGF therapy in the treatment of pLCENC [25]. Recently, Muto et al. [26] reported a salvage therapy case with combined LCNEC with adenocarcinoma harboring an EGFR mutation (exon19, E746–A750 deletion) achieved afatinib, erlotinib, and bevacizumab treatment, and the disease remained stable for 10 months [25]. Meanwhile, Wu et al. confirmed anti-angiogenesis agent, endostar, collaborated with PD-1 blockade and had a dramatically synergic effect to suppress tumor growth in the LCC mice model through up-regulating PI3K/akt/mTOR-mediated autophagy and angiogenesis [27]. In the first-line treatment, our patient took a synergistic method, with endostar and immunochemotherapy and reached a persistent SD over 30 months.

In conclusion, our case provides a potentially effective and safe treatment option in advanced and/or metastasis pulmonary LCNEC as the first-line therapy. The limitation of our study is that we reported only one case, which was insufficient to further explore the OS, PFS, and other indices for this malignant disease. Perhaps, the model can be appropriate in a herd of patients with IV stage pLCENC with negative NE markers, high mitotic rates, no RBI and/or TP53 mutations, high TMB, or positive PD-L1 expression. However, it is difficult to draw definitive conclusions based on such limited experience. Our case report may provide a reference for treatment among our peers. At present, immunotherapy has made a breakthrough for NSCLC patients, and it is expected that more clinical studies will be conducted to explore its effectiveness in the treatment of LCNEC.

Acknowledgments: The authors thank Shanghai Tongshu Biotechnology Co., Ltd. for technical support.

Funding information: Authors state no funding is involved.

Author contributions: Rui Meng conceived the study. Yu Xiao and Sijia Zhang collected the materials for this case. Zhenyu Li and Yan Zong drafted and revised the manuscript. Leichong Chen and Kuikui Zhu prepared the figures and participated in writing. Both authors approved the final manuscript.

Conflict of interest: Authors state no conflict of interest.

Data availability statement: The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

References

[1] Derks JL, Hendriks LE, Buikhusien WA, Groen HJM, Thunnissen E, van Suylen R J, et al. Clinical features of large cell neuroendocrine carcinoma: a population-based overview. Eur Respir J. 2016;47(2):615–24.
[2] Afteh T, Huang CH. Treatment of advanced-stage large cell neuroendocrine cancer (LCNEC) of the lung: a tale of two diseases. Front Oncol. 2021;11:667468.
[3] Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, et al. The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol. 2015;10(9):1243–60.
[4] Travis WD. Advances in neuroendocrine lung tumors. Ann Oncol. 2010;21(Suppl 7):vi65–71.
[5] Zacharias J, Nicholson AG, Ladas GP, Goldstraw P. Large cell neuroendocrine carcinoma and large cell carcinomas with neuroendocrine morphology of the lung: prognosis after complete resection and systematic nodal dissection. Ann Thorac Surg. 2003;75(2):348–52.
[6] Derks JL, Rijnsburger N, Hermans BCM, Moonen L, Hillen LM, von der Thüsen JH, et al. Clinical-pathologic challenges in the classification of pulmonary neuroendocrine neoplasms and targets on the horizon for future clinical practice. J Thorac Oncol. 2021;16(10):1632–46.
[7] Niho S, Kenmotsu H, Sekine I, Ishii G, Ishikawa Y, Moguchi M, et al. Combination chemotherapy with irinotecan and cisplatin for large-cell neuroendocrine carcinoma of the lung: a multicenter phase II study. J Thorac Oncol. 2013;8(7):980–4.
[8] Le Treut J, Sault MC, Lena H, Souquet PJ, Vergnenegre A, Le Caer H, et al. Multicentre phase II study of cisplatin-etoposide chemotherapy for advanced large-cell neuroendocrine lung carcinoma: the GFPC 0302 study. Ann Oncol. 2013;24(6):1548–52.
[9] George J, Walter V, Peifer M, Alexandrov LB, Seidel D, Leenders F, et al. Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors. Nat Commun. 2018;9(1):1048.
[10] Lantuejoul S, Fernandez-Cuesta L, Damiola F, Girard N, McLeer A. New molecular classification of large cell neuroendocrine carcinoma and small cell lung carcinoma with potential therapeutic impacts. Transl Lung Cancer Res. 2020;9(5):2233–44.

[11] Derks JL, Leblay N, Thunnissen E, van Suylen RJ, den Bakker M, Groen HJM, et al. Molecular subtypes of pulmonary large-cell neuroendocrine carcinoma predict chemotherapy treatment outcome. Clin Cancer Res. 2018;24(1):33–42.

[12] Han Y, Pang L, Huang J, Chen J. Large cell neuroendocrine carcinoma of the lungs: case report and literature review. Ann Palliat Med. 2020;9(5):3705–9.

[13] Naidoo J, Santos-Zabala ML, Iyriboz T, Woo KM, Sima CS, Fiore JJ, et al. Large cell neuroendocrine carcinoma of the lung: clinico-pathologic features, treatment, and outcomes. Clin Lung Cancer. 2016;17(5):e121–9.

[14] Rekhtman N, Pietanza MC, Hellmann MD, Naidoo J, Arora A, Won H, et al. Next-generation sequencing of pulmonary large cell neuroendocrine carcinoma reveals small cell carcinoma-like and non-small cell carcinoma-like subsets. Clin Cancer Res. 2016;22(14):3618–29.

[15] Sherman S, Rotem O, Shochat T, Zer A, Moore A, Dudnik E. Efficacy of immune check-point inhibitors (ICPI) in large cell neuroendocrine tumors of lung (LCNEC). Lung Cancer (Amsterdam). 2020;143:40–6.

[16] Levrin MG, Mazieres J, Valette CA, Molinier O, Planchar D, Frappat V, et al. P1.07-012 Efficacy of immune checkpoint inhibitors in large cell neuroendocrine lung cancer: results from a french retrospective cohort: topic: drug treatment alone and in combination with radiotherapy. J Thorac Oncol. 2017;12(1):S702–3.

[17] Chen F, Hua H, Huang H. Neoadjuvant chemotherapy combined with immunotherapy for pulmonary large-cell neuroendocrine carcinoma: a case report. Ann Palliat Med. 2021;10(7):8479–83.

[18] Komiyi T, Ravindra N, Powell E. Role of immunotherapy in stage IV large cell neuroendocrine carcinoma of the lung. Asian Pac J Cancer Prev. 2021;22(2):365–70.

[19] Sabari JK, Julian RA, Ni A, Halpenny D, Hellmann MD, Drilon AE, et al. Outcomes of advanced pulmonary large cell neuroendocrine carcinoma stratified by RB1 loss, SLFN11 expression, and tumor mutational burden. J Clin Oncol. 2018;36(15_suppl):e20568.

[20] Tsuruoka K, Horinouchi H, Goto Y, Kanda S, Fujiwara Y, Nokihiara H, et al. PD-L1 expression in neuroendocrine tumors of the lung. Lung Cancer (Amsterdam). 2017;108:115–20.

[21] Chae YK, Tamragouri K, Chung J, Schrock AB, Kolla B, Ganesan S, et al. Genomic alterations (GA) and tumor mutational burden (TMB) in large cell neuroendocrine carcinoma of lung (L-LCNEC) as compared to small cell lung carcinoma (SCLC) as assessed via comprehensive genomic profiling (CGP). J Clin Oncol. 2017;35(15_suppl):8517.

[22] Zhang X, Sun Y, Miao Y, Xu S. Immune checkpoint inhibitor therapy achieved complete response for drug-sensitive egfr/alk mutation-negative metastatic pulmonary large-cell neuroendocrine carcinoma with high tumor mutation burden: a case report. OncoTargets Ther. 2020;13:8245.

[23] Xu J, Feng Q, Chen Y, Liu XL, Jiang O. Complete remission of combined pulmonary large cell neuroendocrine carcinoma: a case report. J Int Med Res. 2021;49(11):3000605211055387.

[24] Tiseo M, Boni L, Ambrosio F, Camerini A, Baldini E, Cinieri S, et al. Italian, multicenter, phase III, randomized study of cisplatin plus etoposide with or without bevacizumab as first-line treatment in extensive-disease small-cell lung cancer: The GOIRC-AIFA FARM6PMFJM trial. J Clin Oncol. 2017;35(12):1281–7.

[25] Iyoda A, Travis WD, Sarkaria JS, Jiang S-X, Amano H, Sato Y, et al. Expression profiling and identification of potential molecular targets for therapy in pulmonary large-cell neuroendocrine carcinoma. Exp Ther Med. 2011;2(6):1041–5.

[26] Muto S, Ozaki Y, Okabe N, Matsumura Y, Hasegawa T, Shio Y, et al. Successful treatment of combined large cell neuroendocrine carcinoma harboring an egfr mutation with EGFR-TKIs plus bevacizumab: a case report. Case Rep Oncol. 2020;13(3):1387–92.

[27] Wu J, Zhao X, Sun Q, Jiang Y, Zhang W, Luo J, et al. Synergic effect of PD-1 blockade and endostar on the PI3K/AKT/mTOR-mediated autophagy and angiogenesis in Lewis lung carcinoma mouse model. Biomed Pharmacother. 2020;125:109746.
## Appendix

**Table A1:** The serum CA125, FT3, FT4, and TSH levels during the patient’s diagnosis and treatment

| Number | Date       | CA125 | Number | Date       | TSH   | FT3  | FT4  |
|--------|------------|-------|--------|------------|-------|------|------|
| 1      | 2018.6.4   | 170.7 | 1      | 2018.7.31  | 1.2882| 2    | 10.2 |
| 2      | 2018.7.5   | 157.8 | 2      | 2018.8.26  | 2.2358| 2.5  | 10.6 |
| 3      | 2018.7.27  | 21.9  | 3      | 2018.10.15 | 2.4252| 2.7  | 11.2 |
| 4      | 2018.8.21  | 15.6  | 4      | 2018.11.22 | 5.2652| 3.6  | 12.1 |
| 5      | 2018.9.18  | 19.8  | 5      | 2018.12.25 | 3.3175| 3.8  | 10.4 |
| 6      | 2018.10.15 | 21.9  | 6      | 2019.1.29  | 5.7141| 4    | 9.9  |
| 7      | 2018.11.22 | 14.6  | 7      | 2019.4.9   | 16.6002| 4.2 | 10   |
| 8      | 2018.12.25 | 15.3  | 8      | 2019.8.6   | 128.048| 2   | 5.3  |
| 9      | 2019.1.29  | 14.2  | 9      | 2019.9.5   | 75.041| 1.8  | 6.7  |
| 10     | 2019.3.5   | 14.4  | 10     | 2019.10.12 | 46.2223| 3.5 | 10.2 |
| 11     | 2019.4.9   | 14    | 11     | 2020.5.28  | 104.7989| 3.8 | 7.6  |
| 12     | 2019.5.17  | 16    | 12     | 2020.7.22  | 101.9509| 3.2 | 6    |
| 13     | 2019.6.27  | 17.3  | 13     | 2020.12.2  | 131.5156| 2.3 | 5.9  |
| 14     | 2019.8.6   | 19.8  | 14     | 2020.12.30 | 147.5986| 2.3 | 6.4  |
| 15     | 2019.9.5   | 25    |        |            |       |      |      |
| 16     | 2019.10.12 | 37.5  |        |            |       |      |      |
| 17     | 2019.11.19 | 31.3  |        |            |       |      |      |
| 18     | 2019.12.24 | 21.2  |        |            |       |      |      |
| 19     | 2020.5.28  | 46.4  |        |            |       |      |      |
| 20     | 2020.7.22  | 53.4  |        |            |       |      |      |
| 21     | 2020.12.2  | 79.9  |        |            |       |      |      |
| 22     | 2020.12.30 | 287.8 |        |            |       |      |      |
| 23     | 2021.1.23  | 92.6  |        |            |       |      |      |